Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 13/20 | 0.72 |
| ▸ | MAOA | P21397 | 10/20 | 0.72 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.59 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.55 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.54 |
| ▸ | CDK1 | P06493 | 1/20 | 0.54 |
| ▸ | CDK4 | P11802 | 1/20 | 0.54 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.54 |
| ▸ | CCND1 | P24385 | 1/20 | 0.54 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.54 |
| ▸ | RXRA | P19793 | 1/20 | 0.54 |
| ▸ | RXRB | P28702 | 1/20 | 0.54 |
| ▸ | RXRG | P48443 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18002417 | 0.94 | MAOB (0.68) | MAOBMAOANPC1RAB9ATDP1 | |
| SCHEMBL31384348 | 0.89 | MAOB (0.56) | MAOBMAOANR4A2RXRARXRB | |
| SCHEMBL30821439 | 0.86 | MAOB (0.74) | MAOBMAOANPC1RAB9ATDP1 | |
| SCHEMBL3423658 | 0.86 | MAOB (0.65) | MAOBMAOARAB9ANR4A2RXRA | |
| SCHEMBL8985612 | 0.86 | MAOB (0.74) | MAOBMAOANPC1RAB9ATDP1 | |
| SCHEMBL30399352 | 0.86 | MAOB (0.65) | MAOBMAOARAB9ANR4A2RXRA | |
| SCHEMBL29454637 | 0.84 | MAOB (1.00) | MAOBMAOANPC1RAB9ATDP1 | |
| SCHEMBL314161 | 0.84 | MAOB (1.00) | MAOBMAOANPC1RAB9ATDP1 | |
| SCHEMBL8370467 | 0.84 | MAOA (0.66) | MAOBMAOANPC1RAB9ATDP1 | |
| SCHEMBL18918558 | 0.83 | MAOB (0.74) | MAOBMAOANPC1RAB9ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107151220-B | Phenol compound containing benzyloxy phenyl, preparation method and application thereof | 中国医学科学院药物研究所 | 2021-07-20 | — | — | CN | disclosed |
| US-20170342025-A1 | ANTIMICROBIAL COMPOUNDS, COMPOSITIONS AND METHODS | THE UNIVERSITY OF BATH (GB) | 2017-11-30 | — | — | US | disclosed |
| EP-3240775-A2 | ANTIMICROBIAL COMPOUNDS, COMPOSITIONS AND METHODS | Swansea University (GB) | 2017-11-08 | — | — | EP | disclosed |
| WO-2016108045-A2 | ANTIMICROBIAL COMPOUNDS, COMPOSITIONS AND METHODS | SWANSEA UNIVERSITY (GB) | 2016-07-07 | — | — | WO | disclosed |
| US-20140121213-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED (GB) | 2014-05-01 | — | — | US | disclosed |
| US-20140121213-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED (GB) | 2014-05-01 | — | — | US | disclosed |
| US-20130023541-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED | 2013-01-24 | — | — | US | disclosed |
| US-20130023541-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED | 2013-01-24 | — | — | US | disclosed |
| WO-2011088201-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED (GB) | 2011-07-21 | — | — | WO | disclosed |
| US-5550292-A | ANXIOLYTIC AND ANTIDEPRESSANT AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1996-08-27 | — | — | US | disclosed |
| CN-1114106-A | Benzylamine derivatives | OTSUKA PHARMA CO LTD (JP) | 1995-12-27 | — | — | CN | disclosed |
| EP-0666840-A1 | BENZYLAMINE DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-08-16 | — | — | EP | disclosed |
| WO-1995006630-A1 | BENZYLAMINE DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342025-A1 | ANTIMICROBIAL COMPOUNDS, COMPOSITIONS AND METHODS | ZYX, MPO, CFB | MAOB 56/4885MAOA 206/4885NPC1 903/4885 |
| US-20130023541-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | KCNB1, KCNB2, SCNN1B | MAOB 777/4885MAOA 1655/4885NPC1 670/4885 |
| US-20140121213-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | KCNB1, SCNN1B, TRPV1 | MAOB 773/4885MAOA 1446/4885NPC1 620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.